Posted inClinical Updates Gastroenterology Neurology
Elevated Risk of Inflammatory Bowel Disease Following Anti-CD20 Therapy in Multiple Sclerosis Patients: Insights from a Swedish Population-Based Cohort
A Swedish cohort study reveals increased risk of inflammatory bowel disease in relapsing-remitting multiple sclerosis patients treated with rituximab compared to other therapies and the general population, underscoring the need for gastrointestinal vigilance during anti-CD20 treatment.